Yunnan Baiyao Group Co., Ltd., commonly known as Yunnan Baiyao, is a leading Chinese pharmaceutical company headquartered in Kunming, Yunnan Province, China. Established in 1902, the company has a rich history marked by significant milestones in traditional Chinese medicine and modern healthcare. Specialising in the production of herbal medicines, Yunnan Baiyao is renowned for its unique formulations, particularly its haemostatic products that are widely used in both clinical and home settings. The company has carved a prominent position in the pharmaceutical industry, recognised for its commitment to quality and innovation. With a strong presence in both domestic and international markets, Yunnan Baiyao continues to expand its product range, which includes traditional remedies and modern healthcare solutions, solidifying its reputation as a pioneer in the integration of traditional and contemporary medicine.
How does Yunnan Baiyao's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Yunnan Baiyao's score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Yunnan Baiyao reported total carbon emissions of approximately 28,983,100 kg CO2e from Scope 1 and 365,450 kg CO2e from Scope 2, resulting in a combined total of about 29,349,710 kg CO2e for these two scopes. The company has not disclosed any Scope 3 emissions data. Currently, Yunnan Baiyao does not have any publicly stated reduction targets or climate pledges, indicating a potential area for future commitment. The emissions data is sourced directly from Yunnan Baiyao Group Co., Ltd, with no cascading from a parent or related organization. As the company continues to operate within the pharmaceutical industry, it may face increasing pressure to enhance its climate commitments and reduce its carbon footprint in line with global sustainability trends.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 28,983,100 |
| Scope 2 | 365,450 |
| Scope 3 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Yunnan Baiyao is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
